A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond : Episode 2

Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

Mar 15, 2023

Kathryn E. Beckermann, MD, PhD
Moshe Ornstein, MD, MA

Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.

EP: 1.Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP: 2.Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

EP: 3.Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP: 4.Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

Related Videos

Experts on renal cell carcinoma

Experts on renal cell carcinoma

Experts on renal cell carcinoma

Experts on renal cell carcinoma

Expert on urothelial carcinoma

Matthew Galsky, MD

Jonathan Chatzkel, MD

Related Content

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

Related Content

Christopher W. Ryan, MD

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Timothy Yap, MBBS, PhD, FRCP

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

Bradley A. McGregor, MD

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

Toni Choueiri, MD

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

Latest Conference Coverage

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.